Atea Pharmaceuticals, Inc. (AVIR)
Nasdaq · Healthcare · Biotechnology
$5.130.00%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $412M
- 52-week range
- $2.87 – $6.45
- 52-week change
- +72.73%
- EPS (trailing)
- −$2.10
- Next earnings
- Nov 11, 2026
Fiscal year to Dec 2025
- Net income
- −$158M
- Diluted EPS
- −$1.94
From the company’s annual report on SEC EDGAR.
About Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Headquarters: Boston, United States · 55 employees · ateapharma.com